AMP-activated protein kinase inhibitor decreases prostaglandin $F_{2\alpha}$-stimulated interleukin-6 synthesis through p38 MAP kinase in osteoblasts

AKIRA KONDO[1,2], TAKANOBU OTSUKA[1], KENJI KATO[1,2], HIDEO NATSUME[1,2],
GEN KUROYANAGI[1,2], JUN MIZUTANI[1], YOSHIKI ITO[2], RIE MATSUSHIMA-NISHIWAKI[2],
OSAMU KOZAWA[2] and HARUHIKO TOKUDA[2,3]

[1]Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601;
[2]Department of Pharmacology, Gifu University Graduate School of Medicine, Gifu 501-1194;
[3]Department of Clinical Laboratory, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8511, Japan

Abstract. We previously showed that prostaglandin $F_{2\alpha}$ ($PGF_{2\alpha}$) stimulates the synthesis of interleukin-6 (IL-6), a potent bone resorptive agent, in part via p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase but not stress-activated protein kinase/c-*Jun* N-terminal kinase (SAPK/JNK) among the MAP kinase superfamily in osteoblast-like MC3T3-E1 cells. In the present study, we investigated the involvement of AMP-activated protein kinase (AMPK), an intracellular energy sensor, in $PGF_{2\alpha}$-stimulated IL-6 synthesis in MC3T3-E1 cells. $PGF_{2\alpha}$ time-dependently induced the phosphorylation of the AMPK α-subunit. Compound C, an inhibitor of AMPK, dose-dependently suppressed $PGF_{2\alpha}$-stimulated IL-6 release. Compound C reduced the $PGF_{2\alpha}$-induced acetyl-CoA carboxylase phosphorylation. In addition, $PGF_{2\alpha}$-stimulated IL-6 release in human osteoblasts was also inhibited by compound C. The IL-6 mRNA expression induced by $PGF_{2\alpha}$ was markedly reduced by compound C. Downregulation of the AMPK α1-subunit by short interfering RNA (siRNA) significantly suppressed the $PGF_{2\alpha}$-stimulated IL-6 release. $PGF_{2\alpha}$-induced phosphorylation of p38 MAP kinase was inhibited by compound C, which failed to affect the p44/p42 MAP kinase phosphorylation. These results strongly suggest that AMPK regulates $PGF_{2\alpha}$-stimulated IL-6 synthesis via p38 MAP kinase in osteoblasts.

Introduction

AMP-activated protein kinase (AMPK) is generally known to regulate multiple metabolic pathways (1). AMPK has been identified as a mammalian protein kinase that is allosterically activated by AMP and is able to phosphorylate and inactivate enzymes of lipid synthesis (1). It is currently recognized that AMPK is a key sensing enzyme involved in the regulation of cellular energy homeostasis (2-4). AMPK is activated in mammalian cells by a variety of physiological and pathological stresses that increase the intracellular AMP:ATP ratio, either by increasing ATP consumption or by decreasing ATP production. Activated AMPK acts to restore cellular energy balance by ATP-generating pathways such as fatty acid oxidation, while simultaneously inhibiting ATP-utilizing pathways. It is well recognized that bone metabolism is regulated mainly by two functional cells, osteoblasts and osteoclasts (5). The former cells are responsible for bone formation and the latter cells are responsible for bone resorption. These functional cells are closely coordinated via humoral factors or by direct cell-to-cell interaction (5,6). Regarding AMPK in bone metabolism, it has been shown that activated AMPK regulates bone formation and bone mass *in vitro* (7,8). In osteoblasts, activation of AMPK reportedly stimulates their differentiation and inhibits apoptosis (9,10). We previously showed that AMPK plays a role in vascular endothelial growth factor synthesis in osteoblast-like MC3T3-E1 cells (11). However, the exact role of AMPK in bone metabolism has not yet been elucidated.

It is well known that interleukin-6 (IL-6) is a multifunctional cytokine that has crucial effects on a variety of cell functions such as promoting B-cell differentiation, T-cell activation and inducing acute phase proteins (6,12,13). With regard to bone metabolism, IL-6 has been shown to promote osteoclast formation and stimulate bone resorption (6,13-15). It has been reported that potent bone resorptive agents such as tumor necrosis factor-α, IL-1 and prostaglandin (PG) E_2 stimulate IL-6 synthesis in osteoblasts (14,16,17). Evidence suggests that IL-6, which is synthesized and secreted from osteoblasts, plays an important role as a downstream effector of bone resorptive agents in bone metabolism. It is well known that PGs act as autocrine/paracrine modulators of osteoblasts (18). Among them, prostaglandin $F_{2\alpha}$ ($PGF_{2\alpha}$)

Correspondence to: Dr Haruhiko Tokuda, Department of Clinical Laboratory, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8511, Japan
E-mail: tokuda@ncgg.go.jp

is recognized to be a potent bone resorptive agent in bone metabolism. It has been reported that PGF$_{2\alpha}$ stimulates the proliferation of osteoblasts and inhibits the differentiation (18). We previously reported that PGF$_{2\alpha}$ stimulates the IL-6 synthesis in osteoblast-like MC3T3-E1 cells (19) and that p44/ p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase among the MAP kinase superfamily play a role in PGF$_{2\alpha}$-induced IL-6 synthesis in these cells (20,21). However, the detailed mechanism behind the PGF$_{2\alpha}$-stimulated IL-6 synthesis in osteoblasts remains to be clarified.

In the present study, we investigated the involvement of AMPK in PGF$_{2\alpha}$-stimulated IL-6 synthesis in osteoblast-like MC3T3-E1 cells. We herein showed that AMPK positively regulates PGF$_{2\alpha}$-stimulated IL-6 synthesis at a point upstream from p38 MAP kinase activation in these cells.

Materials and methods

Materials. PGF$_{2\alpha}$ and mouse IL-6 enzyme-linked immu-nosorbent assay (ELISA) kit were purchased from R&D Systems, Inc. (Minneapolis, MN). Compound C was obtained from Calbiochem-Novabiochem Co. (La Jolla, CA). Normal human osteoblasts (NHOst) were purchased from Cambrex (Charles City, IA). Phospho-specific AMPK α-subunit (Thr-172), phospho-specific AMPK α-subunit (Ser-485), AMPK α-subunit, phospho-specific AMPK β-subunit (Ser-108), phospho-specific AMPK β-subunit (Ser-182), AMPK β-subunit, phospho-specific acetyl-CoA carboxylase, phospho-specific p44/p42 MAP kinase, p44/p42 MAP kinase, phospho-specific p38 MAP kinase and p38 MAP kinase antibodies were purchased from Cell Signaling Technology, Inc. (Beverly, MA). The GAPDH antibody was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). An ECL western blotting detection system was purchased from GE Healthcare UK, Ltd. (Buckinghamshire, UK). Control short interfering RNA (siRNA) (Silencer® Negative Control #1 siRNA) was purchased from Ambion (Austin, TX). AMPK α1-subunit siRNA (SI0 1388219) and the OmniScript Reverse Transcriptase kit were purchased from Qiagen GmbH (Hilden, Germany). siLentFect™ was purchased from Bio-Rad (Hercules, CA). TRIzol reagent was purchased from Invitrogen (Carlsbad, CA). Fast Start DNA Master SYBR-Green I was purchased from Roche Diagnostics (Mannheim, Germany). Other materials and chemicals were obtained from commercial sources.

Cell culture. Cloned osteoblast-like MC3T3-E1 cells that were derived from newborn mouse calvaria (22) were maintained as previously described (23). Briefly, the cells were cultured in α-minimum essential medium (α-MEM) containing 10% fetal calf serum (FCS) at 37°C in a humidified atmosphere of 5% CO$_2$/95% air. The cells were seeded into 35-mm (5x10^4) or 90-mm (2x10^5) diameter dishes in α-MEM containing 10% FCS. After 5 days, the medium was replaced with α-MEM containing 0.3% FCS. The cells were used for experiments after 48 h.

NHOst were seeded into 35-mm (5x10^4) diameter dishes in α-MEM containing 10% FCS. After 6 days, the medium was replaced with α-MEM containing 0.3% FCS. The cells were used for experiments after 48 h.

IL-6 assay. The cultured cells were stimulated with 10 μM PGF$_{2\alpha}$ in 1 ml of α-MEM containing 0.3% FCS for the indicated periods. When indicated, the cells were pretreated with various doses of compound C for 60 min. The conditioned medium was collected at the end of the incubation and the IL-6 concentration was measured by the IL-6 ELISA kit.

siRNA transfection. To knock down the AMPK α-subunit in MC3T3-E1 cells, the cells were transfected with the control siRNA or the AMPK α1-subunit siRNA using siLentFect according to the manufacturer's protocol. In brief, the cells (1x10^5) were seeded in a 35-mm diameter dish in α-MEM containing 10% FCS and subcultured for 48 h. The cells were then incubated with 50 nM siRNA-siLentFect complexes. After 24 h, the medium was replaced with α-MEM containing 0.3% FCS. The cells were used for experiments after 24 h.

Western blot analysis. Western blot analysis was performed as previously described (24). The cultured cells were stimulated with PGF$_{2\alpha}$ or vehicle in α-MEM containing 0.3% FCS for the indicated periods. When indicated, the cells were pretreated with various doses of compound C for 60 min. The cells were washed twice with phosphate-buffered saline and then lysed, homogenized and sonicated in a lysis buffer containing 62.5 mM Tris/HCl (pH 6.8), 3% sodium dodecyl sulfate (SDS), 50 mM dithiothreitol and 10% glycerol. The cytosolic fraction was collected as a supernatant after centrifugation at 125,000 x g for 10 min at 4°C. SDS-polyacrylamide gel electrophoresis (PAGE) was performed according to Laemmli *et al* (25) on 10% polyacrylamide gel. The protein (20 μg) was fractionated and transferred onto an Immun-Blot® PVDF Membrane (Bio-Rad, Hercules, CA). Membranes were blocked with 5% fat-free dry milk in Tris-buffered saline-Tween [TBS-T; 20 mM Tris/HCl (pH 7.6), 137 mM NaCl, 0.1% Tween-20] for 2 h before incubation with the primary antibodies. Phospho-specific AMPK α-subunit (Thr-172), phospho-specific AMPK α-subunit (Ser-485), AMPK α-subunit, phospho-specific AMPK β-subunit (Ser-108), phospho-specific AMPK β-subunit (Ser-182), AMPK β-subunit, phospho-specific acetyl-CoA carboxylase, phospho-specific p44/p42 MAP kinase, p44/p42 MAP kinase, phospho-specific p38 MAP kinase, p38 MAP kinase, phospho-specific SAPK/JNK and SAPK/JNK antibodies or GAPDH antibody were used as primary antibodies. Peroxidase-labeled antibody raised in goat against rabbit IgG (KPL, Inc., Gaithersburg, MD) was used as the secondary antibody. The primary and secondary antibodies were diluted at 1:1,000 with 5% fat-free dry milk in TBS-T. Peroxidase activity on the membrane was visualized on X-ray film by means of the ECL western blotting detection system.

Real-time RT-PCR. The cultured cells were stimulated with 10 μM PGF$_{2\alpha}$ for the indicated periods. Total RNA was isolated and transcribed into cDNA using TRIzol reagent and the OmniScript Reverse Transcriptase kit. Real-time RT-PCR was performed using a Light Cycler system (Roche Diagnostics, Basel, Switzerland) in the capillaries and Fast Start DNA Master SYBR-Green I provided with the kit. Sense and antisense primers for mouse IL-6 and GAPDH mRNA were purchased from Takara Bio, Inc. (Tokyo, Japan) (primer

Figure 1. Effects of $PGF_{2\alpha}$ on the phosphorylation of AMP-activated protein kinase (AMPK) in MC3T3-E1 cells. The cultured cells were stimulated with 10 μM $PGF_{2\alpha}$ for the indicated periods. The extracts of cells were subjected to SDS-PAGE with subsequent western blot analysis with antibodies against phospho-specific AMPK α-subunit (Thr-172), phospho-specific AMPK α-subunit (Ser-485), AMPK α-subunit, phospho-specific AMPK β-subunit (Ser-108), phospho-specific AMPK β-subunit (Ser-182) or AMPK β-subunit.

set ID MA039013). The amplified products were determined by a melting curve analysis and agarose electrophoresis. IL-6 mRNA levels were normalized with those of GAPDH mRNA.

Determination. The absorbance of enzyme immunoassay samples was measured at 450 nm with an EL 340 Bio Kinetic Reader (Bio-Tek Instruments, Inc., Winooski, VT).

Statistical analysis. Data were analyzed by ANOVA followed by the Bonferroni method for multiple comparisons between pairs and a $P<0.05$ was considered to indicate a statistically significant difference. All data are presented as the means ± SEM of triplicate independent determinations.

Results

Effect of $PGF_{2\alpha}$ on the phosphorylation of AMP-activated protein kinase in MC3T3-E1 cells. It is generally known that the phosphorylation of AMPK is essential for its activation (26). Therefore, we first examined the effect of $PGF_{2\alpha}$ on the phosphorylation of AMPK in osteoblast-like MC3T3-E1 cells in order to clarify whether $PGF_{2\alpha}$ induces the activation of AMPK in osteoblasts. $PGF_{2\alpha}$ markedly stimulated the phosphorylation of the AMPK α-subunit (Thr-172) (Fig. 1). In contrast, levels of phosphorylated AMPK β-subunit (Ser-108) or phosphorylated AMPK β-subunit (Ser-182) were barely affected by $PGF_{2\alpha}$ (Fig. 1). The effect of $PGF_{2\alpha}$ on the phosphorylation of AMPK α-subunit (Thr-172) reached its peak within 2 min and thereafter decreased.

Effect of compound C on $PGF_{2\alpha}$-stimulated IL-6 release in MC3T3-E1 cells. In our previous study (19), we showed that $PGF_{2\alpha}$ stimulates IL-6 synthesis in osteoblast-like MC3T3-E1 cells. In order to investigate whether AMPK plays a role in $PGF_{2\alpha}$-induced synthesis of IL-6 in MC3T3-E1 cells, we examined the effect of compound C, an inhibitor of AMPK (27), on the $PGF_{2\alpha}$-stimulated release of IL-6. Compound C significantly reduced $PGF_{2\alpha}$-stimulated IL-6 release (Fig. 2). The suppressive effect of compound C on the IL-6 release was


Figure 2. Effect of compound C on $PGF_{2\alpha}$-induced IL-6 synthesis in MC3T3-E1 cells. The cultured cells were pretreated with various doses of compound C for 60 min, and then stimulated with 10 μM $PGF_{2\alpha}$ or vehicle for 48 h. Each value represents the means ± SEM of triplicate independent determinations. *$P<0.05$, compared to the value of $PGF_{2\alpha}$ alone.


Figure 3. Time-dependent effect of $PGF_{2\alpha}$ on the phosphorylation of acetyl-CoA carboxylase in MC3T3-E1 cells. The cultured cells were stimulated with 10 μM $PGF_{2\alpha}$ for the indicated periods. The extracts of cells were subjected to SDS-PAGE with subsequent western blot analysis with antibodies against phospho-specific acetyl-CoA carboxylase or GAPDH.

dose-dependent in the range between 1 and 20 μM. Twenty micromoles of compound C caused an ~55% inhibition in the $PGF_{2\alpha}$ effect.

Effects of $PGF_{2\alpha}$ on the phosphorylation of acetyl-CoA carboxylase in MC3T3-E1 cells. Acetyl-CoA carboxylase, which regulates lipid synthesis, is a direct substrate of AMPK (1). $PGF_{2\alpha}$ markedly induced the phosphorylation of acetyl-CoA carboxylase in MC3T3-E1 cells (Fig. 3). The effect of $PGF_{2\alpha}$ on acetyl-CoA carboxylase phosphorylation reached a peak within 6 min and thereafter decreased. Compound C reduced the $PGF_{2\alpha}$-induced phosphorylation level of acetyl-CoA carboxylase in a dose-dependent manner (Fig. 4).

Effect of compound C on the $PGF_{2\alpha}$-stimulated IL-6 release in human osteoblasts. In addition, we examined the effect of compound C (27), on $PGF_{2\alpha}$-induced release of IL-6 in another type of osteoblast, NHOst, a human osteoblastic cell type. We found that $PGF_{2\alpha}$ markedly stimulated IL-6 release in NHOst. Compound C significantly suppressed the $PGF_{2\alpha}$-induced release of IL-6 (Fig. 5). Compound C (1 μM) caused an ~45% inhibition in the $PGF_{2\alpha}$ effect.

Figure 4. Effect of compound C on PGF$_{2\alpha}$-induced phosphorylation of acetyl-CoA carboxylase in MC3T3-E1 cells. The cultured cells were pre-treated with various doses of compound C for 60 min, and then stimulated with 10 μM PGF$_{2\alpha}$ or vehicle for 3 min. The extracts of cells were subjected to SDS-PAGE with subsequent western blot analysis with antibodies against phospho-specific acetyl-CoA carboxylase or GAPDH.


Figure 5. Effect of compound C on PGF$_{2\alpha}$-induced IL-6 synthesis in NHOst cells. The cultured cells were pretreated with 1 μM of compound C or vehicle for 60 min, and then stimulated with 10 μM PGF$_{2\alpha}$ for 48 h. Values of PGF$_{2\alpha}$-unstimulated cells were subtracted to produce each data point. Each value represents the means ± SEM of triplicate independent determinations. *P<0.05, compared to the value of PGF$_{2\alpha}$ alone.

Figure 6. Effect of compound C on PGF$_{2\alpha}$-induced IL-6 mRNA expression in MC3T3-E1 cells. The cultured cells were pretreated with 3 μM of compound C or vehicle for 60 min, and then stimulated with 10 μM PGF$_{2\alpha}$ or vehicle for 6 h. Each value represents the means ± SEM of triplicate independent determinations. *P<0.05, compared to the value of control.**P<0.05, compared to the value of PGF$_{2\alpha}$ alone

Figure 7. Effect of AMP-activated protein kinase siRNA on the PGF$_{2\alpha}$-stimulated IL-6 release in MC3T3-E1 cells. The cultured cells were transfected with control siRNA or AMP-activated protein kinase α1-subunit siRNA using siLentFect according to the manufacturer's protocol. The cells were stimulated with 10 μM PGF$_{2\alpha}$ or vehicle for 48 h. Each value represents the means ± SEM of triplicate independent determinations. *P<0.05, compared to the value without PGF$_{2\alpha}$ in control cells. **P<0.05, compared to the value with PGF$_{2\alpha}$ in the control cells.

Effect of compound C on the PGF$_{2\alpha}$-stimulated IL-6 mRNA expression in MC3T3-E1 cells. In order to clarify whether the suppression of PGF$_{2\alpha}$-stimulated IL-6 synthesis by compound C is mediated via a transcriptional event, we examined the effect of compound C on PGF$_{2\alpha}$-induced expression level of IL-6 mRNA in MC3T3-E1 cells. Compound C, which alone had a slight suppressive effect on the basal IL-6 mRNA expression level, significantly reduced the PGF$_{2\alpha}$-induced level of IL-6 mRNA (Fig. 6).

Effect of AMPK siRNA on PGF$_{2\alpha}$-stimulated IL-6 release in MC3T3-E1 cells. To confirm the findings from the compound C experimental series in osteoblast-like MC3T3-E1 cells, we examined the effect of AMPK downregulation by siRNA on the PGF$_{2\alpha}$-stimulated IL-6 release. PGF$_{2\alpha}$-induced levels of IL-6 in AMPK α1-subunit-downregulated cells were markedly suppressed compared with levels in the control siRNA-transfected cells (Fig. 7).

Effects of compound C on PGF$_{2\alpha}$-induced phosphorylation of p44/p42 MAP kinase or p38 MAP kinase in MC3T3-E1 cells.

The MAP kinase superfamily such as p44/p42 MAP kinase, p38 MAP kinase and stress-activated protein kinase/c-*Jun* N-terminal kinase (SAPK/JNK) plays a central role in the transduction of the various messages of a variety of agonists (28). In our previous studies (20,21), we demonstrated that PGF$_{2\alpha}$ induces the activation of p44/p42 MAP kinase, p38 MAP kinase and SAPK/JNK in osteoblast-like MC3T3-E1 cells and that p44/p42 MAP kinase and p38 MAP kinase

Figure 8. Effect of compound C on $PGF_{2\alpha}$-induced phosphorylation of p44/p42 MAP kinase in MC3T3-E1 cells. The cultured cells were pretreated with various doses of compound C for 60 min and then stimulated with 10 μM $PGF_{2\alpha}$ or vehicle for 15 min. The extracts of cells were subjected to SDS-PAGE with subsequent western blot analysis with antibodies against phospho-specific p44/p42 MAP kinase or p44/p42 MAP kinase.

Figure 9. Effect of compound C on $PGF_{2\alpha}$-induced phosphorylation of p38 MAP kinase in MC3T3-E1 cells. The cultured cells were pretreated with various doses of compound C for 60 min and then stimulated with 10 μM $PGF_{2\alpha}$ or vehicle for 5 min. The extracts of cells were subjected to SDS-PAGE with subsequent western blot analysis with antibodies against phospho-specific p38 MAP kinase or p38 MAP kinase.

but not SAPK/JNK function as positive regulators in $PGF_{2\alpha}$-stimulated IL-6 synthesis. In order to elucidate whether the AMPK effect on $PGF_{2\alpha}$-stimulated IL-6 synthesis is due to the activation of these MAP kinases in MC3T3-E1 cells, we examined the effect of compound C on $PGF_{2\alpha}$-induced phosphorylation of p44/p42 MAP kinase or p38 MAP kinase. $PGF_{2\alpha}$-induced phosphorylation of p44/p42 MAP kinase was not suppressed by compound C up to 30 μM (Fig. 8). On the contrary, compound C markedly attenuated the $PGF_{2\alpha}$-induced phosphorylation level of p38 MAP kinase in a dose-dependent manner in the range between 3 and 30 μM (Fig. 9).

Discussion

In the present study, we showed that $PGF_{2\alpha}$ markedly stimulated the phosphorylation of AMP-activated protein kinase (AMPK) α-subunit (Thr-172) among the phosphorylation sites of AMPK in osteoblast-like MC3T3-E1 cells. It is generally recognized that AMPK plays a crucial role as a central regulator of cellular energy homeostasis (2). AMPK is a heterotrimeric complex that consists of three subunits, α, β and γ (26,29). Among the three subunits of AMPK, the α-subunit is recognized to be a catalytic site whereas β- and γ-subunits are considered as regulatory sites. It has been reported that the phosphorylation of the AMPK α-subunit at Thr-172 is essential for enzyme activation (26). We also showed that $PGF_{2\alpha}$ induced acetyl-CoA carboxylase phosphorylation in MC3T3-E1 cells. Acetyl-CoA carboxylase is a downstream target of AMPK, and phosphorylated acetyl-CoA carboxylase inhibits the synthesis of lipids such as fatty acid and cholesterol (1,26). We demonstrate that the time course of $PGF_{2\alpha}$-induced phosphorylation of the AMPK α-subunit at

Thr-172 was more rapid than that of acetyl-CoA carboxylase (Figs. 1 and 3). In addition, we showed that compound C, an inhibitor of AMPK (27), reduced the levels of acetyl-CoA carboxylase phosphorylation induced by $PGF_{2\alpha}$. Based on our findings, it is most likely that $PGF_{2\alpha}$ stimulates the activation of AMPK in osteoblast-like MC3T3-E1 cells.

We next investigated whether AMPK activation plays a role in $PGF_{2\alpha}$-stimulated IL-6 synthesis in osteoblast-like MC3T3-E1 cells. Compound C significantly inhibited the $PGF_{2\alpha}$-stimulated release of IL-6 in a dose-dependent manner. These findings suggest that the AMPK activated by $PGF_{2\alpha}$ is involved in IL-6 synthesis in MC3T3-E1 cells. In addition, we showed that compound C markedly inhibited $PGF_{2\alpha}$-induced IL-6 mRNA expression. It is likely that AMPK regulates the synthesis of IL-6. Additionally, we found that compound C suppressed the IL-6 levels stimulated by $PGF_{2\alpha}$ in NHOst, a human osteoblast cell type. Thus, it is probable that the effect of compound C on $PGF_{2\alpha}$-induced IL-6 synthesis is common in mammalian osteoblasts. Furthermore, we demonstrated that downregulation of AMPK by siRNA markedly reduced the $PGF_{2\alpha}$-stimulated IL-6 release in MC3T3-E1 cells. Taking our results into account, it is likely that $PGF_{2\alpha}$ stimulates the activation of AMPK in osteoblast-like MC3T3-E1 cells and that AMPK positively regulates $PGF_{2\alpha}$-induced IL-6 synthesis.

In our previous studies (20,21), we reported that p44/p42 MAP kinase and p38 MAP kinase but not SAPK/JNK among the MAP kinase superfamily act as positive regulators in $PGF_{2\alpha}$-stimulated IL-6 synthesis in osteoblast-like MC3T3-E1 cells. Therefore, we investigated the relationship between AMPK and MAP kinase signaling, p44/p42 MAP kinase or p38 MAP kinase in IL-6 synthesis. Compound C markedly suppressed $PGF_{2\alpha}$-induced phosphorylation levels of p38 MAP kinase without affecting the levels of p44/p42 MAP kinase phosphorylation. These findings suggest that AMPK functions in the $PGF_{2\alpha}$-stimulated activation of p38 MAP kinase in osteoblast-like MC3T3-E1 cells. In the present study, we showed that the maximum effect of $PGF_{2\alpha}$ on the phosphorylation of the AMPK α-subunit (Thr-172) was observed within 2 min after stimulation. In contrast, in our previous study (30), we showed that the phosphorylation of p38 MAP kinase reached a peak at 10 min after the stimulation of $PGF_{2\alpha}$. The time course of $PGF_{2\alpha}$-induced phosphorylation of AMPK appears to be more rapid than that of p38 MAP kinase. Therefore, it is reasonable that $PGF_{2\alpha}$ induces the activation of p38 MAP kinase via AMPK in MC3T3-E1 cells. Collectively, $PGF_{2\alpha}$ stimulates IL-6 synthesis via AMPK, which plays a role at least partly through the regulation of p38 MAP kinase in osteoblast-like MC3T3-E1 cells.

AMPK is a central regulator in cellular energy homeostasis such as lipid synthesis (1,31). With regard to bone metabolism, accumulating evidence suggests that AMPK stimulates bone formation and mineralization, resulting in an increase in bone mass (7,8). As for osteoblast function, it has recently been shown that the activation of AMPK inhibits palmitate-induced apoptosis in osteoblasts (9). AMPK was reported to stimulate osteoblast differentiation via induction of Runx2 expression (10). In addition, it has recently been shown that inhibition of AMPK suppresses osteoprotegerin secretion in osteoblasts (32). Based on our present findings, it is possible that inhibition of AMPK reduces the $PGF_{2\alpha}$-

stimulated IL-6 synthesis in osteoblasts. Osteoporosis is a major clinical problem in advanced countries. The pathology of osteoporosis involves the reduction in bone mineral density, resulting in susceptibility to bone fracture (33). IL-6 synthesized by osteoblasts is generally recognized as a potent bone resorptive agent and induces osteoclast formation (6,14). Therefore, we speculate that PGF$_{2\alpha}$-activated AMPK in osteoblasts is a potent modulator in bone metabolism via the fine-tuning of the local cytokine network, such as synthesis of IL-6. The appropriate regulation of AMPK in osteoblasts may be a potential molecular therapeutic strategy for bone metabolic disease such as osteoporosis. However, the detailed mechanisms of AMPK in bone metabolism are not precisely known. Further investigation is necessary to clarify the exact roles of AMPK in osteoblasts.

Taken together, our results revealed that an AMPK inhibitor decreases PGF$_{2\alpha}$-stimulated IL-6 synthesis via suppression of p38 MAP kinase in osteoblasts.

Acknowledgements

References

1. Fogarty S and Hardie DG: Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 1804: 581-591, 2010.
2. Hardie DG, Hawley SA and Scott JW: AMP-activated protein kinase - development of the energy sensor concept. J Physiol 574: 7-15, 2006.
3. Lage R, Dieguez C, Vidal-Puig A and Lopez M: AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med 14: 539-549, 2008.
4. Steinberg GR and Kemp BE: AMPK in health and disease. Physiol Rev 89: 1025-1078, 2009.
5. Karsenty G and Wagner EF: Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2: 389-406, 2002.
6. Kwan Tat S, Padrines M, Theoleyre S, Heymann D and Fortun Y: IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15: 49-60, 2004.
7. Shah M, Kola B, Bataveljic A, Arnett TR, Viollet B, Saxon L, Korbonits M and Chenu C: AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. Bone 47: 309-319, 2010.
8. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M and Sugimoto T: Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMPK activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 375: 414-419, 2008.
9. Kim JE, Ahn MW, Baek SH, Lee IK, Kim YW, Kim JY, Dan JM and Park SY: AMPK activator, AICAR, inhibits palmitate-induced apoptosis in osteoblast. Bone 43: 394-404, 2008.
10. Jang WG, Kim EJ, Lee KN, Son HJ and Koh JT: AMP-activated protein kinase (AMPK) positively regulates osteoblast differentiation via induction of Dlx5-dependent Runx2 expression in MC3T3E1 cells. Biochem Biophys Res Commun 404: 1004-1009, 2011.
11. Kato K, Tokuda H, Adachi S, Matsushima-Nishiwaki R, Natsume H, Yamakawa K, Gu Y, Otsuka T and Kozawa O: AMP-activated protein kinase positively regulates FGF-2-stimulated VEGF synthesis in osteoblasts. Biochem Biophys Res Commun 400: 123-127, 2010.
12. Akira S, Taga T and Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol 54: 1-78, 1993.
13. Heymann D and Rousselle AV: gp130 Cytokine family and bone cells. Cytokine 12: 1455-1468, 2000.
14. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe F, Nakamura Y, Yamaguchi Y, Yoshiki S, Matsuda T, Hirano T, Kishimoto T and Suda T: IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 145: 3297-3303, 1990.
15. Roodman GD: Interleukin-6: an osteotropic factor? J Bone Miner Res 7: 475-478, 1992.
16. Littlewood AJ, Russell J, Harvey GR, Hughes DE, Russel RGG and Gowen M: The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro. Endocrinology 129: 1513-1520, 1991.
17. Helle M, Brakenhoff JPJ, De Groot ER and Aarden LA: Interleukin 6 is involved in interleukin 1-induced activities. Eur J Immunol 18: 957-959, 1998.
18. Pilbeam CC, Harrison JR and Raisz LG: Prostaglandins and bone metabolism. In: Principles of Bone Biology. Bilezikian JP, Raisz LG and Rodan GA (eds). Academic Press, San Diego, CA, pp979-994, 2002.
19. Kozawa O, Suzuki A, Tokuda H and Uematsu T: Prostaglandin F$_{2\alpha}$ stimulates interleukin-6 synthesis via activation of PKC in osteoblast-like cells. Am J Physiol 272: E208-E211, 1997.
20. Tokuda H, Kozawa O, Harada A and Uematsu T: p42/p44 mitogen-activated protein kinase activation is involved in prostaglandin F$_{2\alpha}$-induced interleukin-6 synthesis in osteoblasts. Cell Signal 11: 325-330, 1999.
21. Minamitani C, Otsuka T, Takai S, Matsushima-Nishiwaki R, Adachi S, Hanai Y, Mizutani J, Tokuda H and Kozawa O: Involvement of Rho-kinase in prostaglandin F$_{2\alpha}$-stimulated interleukin-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts. Mol Cell Endocrinol 291: 27-32, 2008.
22. Sudo H, Kodama H, Amagai Y, Yamamoto S and Kasai S: In vitro differentiation and calcification in a new clonalosteogenic cell line derived from newborn mouse calvaria. J Cell Biol 96: 191-198, 1983.
23. Kozawa O, Tokuda H, Miwa M, Kotoyori J and Oiso Y: Cross-talk regulation between cyclic AMP production and phosphoinositide hydrolysis induced by prostaglandin E$_2$ in osteoblast-like cells. Exp Cell Res 198: 130-134, 1992.
24. Kato K, Ito H, Hasegawa K, Inaguma Y, Kozawa O and Asano T: Modulation of the stress-induced synthesis of hsp27 and α B-crystallin by cyclic AMP in C6 rat glioma cells. J Neurochem 66: 946-950, 1996.
25. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
26. Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D and Hardie DG: Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem 271: 27879-27887, 1996.
27. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ and Moller DE: Role of AMP-activated protein kinase in mechanism of metformin activation. J Clin Invest 108: 1167-1174, 2001.
28. Kyriakis JM and Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869, 2001.
29. Stapleton D, Gao G, Michell BJ, Widmer J, Mitchelhill K, Teh T, House CM, Witters LA and Kemp BE: Mammalian 5'-AMP-activated protein kinase non-catalytic subunits are homologs of proteins that interact with yeast Snf1 protein kinase. J Biol Chem 269: 29343-29346, 1994.
30. Tokuda H, Takai S, Matsushima-Nishiwaki R, Akamatsu S, Hanai Y, Hosoi T, Harada A, Ohta T and Kozawa O: (-)-Epigallocatechin gallate enhances prostaglandin F$_{2\alpha}$-induced VEGF synthesis via up-regulating SAPK/JNK activation in osteoblasts. J Cell Biochem 100: 1146-1153, 2007.
31. Rutter GA and Leclerc I: The AMP-regulated kinase family: enigmatic targets for diabetes therapy. Mol Cell Endocrinol 297: 41-49, 2009.
32. Mai Q, Zhang Z, Xu S, Lu M, Zhou R, Zhao L, Jia C, Wen Z, Jin D and Bai X: Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem 112: 2902-2909, 2011.
33. Unnanuntana A, Gladnick BP, Donnelly E and Lane JM: The assessment of fracture risk. J Bone Joint Surg Am 92: 743-753, 2010.